文献速递淋巴瘤

RENOIR 三期试验:复发难治滤泡性淋巴瘤老年患者中利妥昔单抗联合来那度胺对比利妥昔单抗维持治疗

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

RENOIR 是由 FIL 开展的 multicenter 三期开放标签随机试验,入组 152 例既往接受 1–2 线治疗的复发难治滤泡性淋巴瘤老年患者(中位年龄 71 岁)。诱导后 129 例缓解者随机接受利妥昔单抗(R)或 R 联合来那度胺(R2)维持。中位随访 68 个月,2 年 PFS 在 R2 组为 73%、R 组为 64%,主要终点未达到;R2 组 3/4 级不良事件更常见,主要为中性粒细胞减少和胃肠道反应。

要点

  • R2 维持未显著改善老年复发难治 FL 的 2 年 PFS,主要终点未达到。
  • 探索性亚组显示 <70 岁患者 R2 的 2 年 PFS 为 96% vs R 组 69%。
  • R2 组 3/4 级不良事件更常见,主要为中性粒细胞减少和胃肠道反应。

核心结论

  • RENOIR 主要终点未达到,R2 维持未显著改善老年复发难治 FL 的 2 年 PFS,但观察到数值上的获益。
  • R2 在 <70 岁患者中显示出更有利的获益-风险特征,而老年患者需仔细评估个体耐受性。

研究设计与样本

  • RENOIR 为 Fondazione Italiana Linfomi(FIL)开展的多中心三期开放标签随机试验,注册号 NCT02390869。
  • 入组既往接受 1 或 2 线治疗的复发难治滤泡性淋巴瘤老年患者,共 152 例,中位年龄 71 岁。
  • 经 4–6 周期标准含利妥昔单抗化疗后达到部分缓解或完全缓解者按 1:1 随机接受 R 单药维持(标准 arm)或 R 联合来那度胺维持(R2,试验 arm)。
  • 主要终点为自随机起的 2 年无进展生存期(PFS),预期风险比(HR)为 0.5。
  • 诱导后 129 例(85%)达到总体缓解(完全缓解率 58%),随机至 R 组 n=65、R2 组 n=64。

主要发现

  • 中位随访 68 个月,2 年 PFS 在 R2 组为 73%、R 组为 64%。
  • 非计划假设生成性亚组分析显示 <70 岁患者 R2 的 2 年 PFS 获益更大:R2 组 96% vs R 组 69%。
  • 2 年总生存率两组相似:R2 组 80% vs R 组 89%。
  • 3/4 级不良事件在 R2 组更频繁,主要为中性粒细胞减少和胃肠道疾病。

临床怎么用

  • 老年复发难治 FL 患者选择 R2 维持时需仔细评估个体耐受性,因 3/4 级不良事件更常见。
  • <70 岁患者可考虑 R2 维持,基于探索性亚组显示的 2 年 PFS 数值获益。

局限性

  • 主要终点未达到,R2 维持的 PFS 获益未达统计学显著。
  • <70 岁亚组分析为非计划的假设生成性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Maintenance treatment in older patients with relapsed or refractory (R/R) follicular lymphoma (FL) remains an area of investigation. RENOIR was a multicenter, phase 3, open-label randomized trial conducted by the Fondazione Italiana Linfomi (FIL) in older patients with R/R FL after 1 or 2 previous therapies. Patients achieving partial response or complete response (CR) after 4 to 6 cycles of standard rituximab (R)-based chemotherapy were randomized 1:1 to maintenance with R alone (standard arm) or R plus lenalidomide (R2; experimental arm). The primary end point was 2-year progression-free survival (PFS) from randomization, with an expected hazard ratio (HR) of 0.5. A total of 152 patients (median age, 71 years) were enrolled. After induction, 129 (85%) achieved an overall response (CR, 58%) and were randomized to R (n = 65) or R2 (n = 64). At a median follow-up of 68 months, the 2-year PFS was 73% in the R2 arm and 64% in the R arm. An unplanned hypothesis-generating subgroup analysis showed a greater 2-year PFS benefit with R2 in patients aged <70 years: R2, 96% vs R, 69%. Two-year overall survival rates were similar (R2, 80% vs R, 89%). Grade 3/4 adverse events were more frequent in R2, mainly neutropenia and gastrointestinal disorders. In conclusion, the primary end point of the study was not met, and R2 maintenance did not significantly improve 2-year PFS in older patients with R/R FL, although a numerical benefit was observed. R2 showed a more favorable benefit-risk profile in patients aged <70 years, whereas in older patients careful consideration of individual tolerability is warranted. This trial was registered at www.clinicaltrials.gov as NCT02390869.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Botto B, Boccomini C, Evangelista A, et al. RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma. Blood Adv. 2026. PMID: 42349017. doi:10.1182/bloodadvances.2025018732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。